| 1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA: A Cancer Journal for Clinicians, 2020, 70(1): 7-30.
|
| 2 |
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J]. Chinese Journal of Cancer Research, 2018, 30(1): 1-12.
|
| 3 |
Xu J, Fan J, Qin X, et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018) [J]. Journal of Cancer Research and Clinical Oncology, 2019, 145(3): 725-736.
|
| 4 |
Shin SW, Ahn KS, Kim SW, et al. Liver resection versus local ablation therapies for hepatocellular carcinoma within the milan criteria: a systematic review and meta-analysis[J]. Annals of Surgery, 2021, 273(4): 656-666.
|
| 5 |
Orcutt ST, Anaya DA. Liver resection and surgical strategies for management of primary liver cancer[J]. Cancer Control: Journal of the Moffitt Cancer Center, 2018, 25(1): 1073274817744621.
|
| 6 |
Scherman P, Syk I, Holmberg E, et al. Impact of patient, primary tumor and metastatic pattern including tumor location on survival in patients undergoing ablation or resection for colorectal liver metastases: A population-based national cohort study[J]. European Journal of Surgical Oncology: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, 47(2): 375-383.
|
| 7 |
Rouyer M, François E, Cunha AS, et al. Effectiveness of cetuximab as first-line therapy for patients with wild-type KRAS and unresectable metastatic colorectal cancer in real-life practice: results of the EREBUS cohort[J]. Clinical colorectal cancer, 2018, 17(2): 129-139.
|
| 8 |
Chen HH, Lin JK, Chen JB, et al. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase Ⅱ, open-label, single-arm, noncomparative trial[J]. Asia-Pacific Journal of Clinical Oncology, 2018, 14(1): 61-68.
|
| 9 |
Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) [J]. European Journal of Cancer (Oxford, England: 1990), 2017, 81: 191-202.
|
| 10 |
Takahashi T, Emi Y, Oki E, et al. Multicenter phase Ⅱ study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) [J]. Cancer Chemotherapy and Pharmacology, 2016, 78(3): 585-593.
|
| 11 |
Lévi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2016, 27(2): 267-274.
|
| 12 |
Grothey A, Blay JY, Pavlakis N, et al. Evolving role of regorafenib for the treatment of advanced cancers[J]. Cancer Treatment Reviews, 2020, 86: 101993.
|
| 13 |
Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer[J]. European Journal of Cancer (Oxford, England: 1990), 2019, 109: 70-83.
|
| 14 |
Walter T, Hawkins NS, Pollock RF, et al. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer[J]. Journal of Cancer Research and Clinical Oncology, 2020, 146(10): 2575-2587.
|
| 15 |
Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: Past, present, and future[J]. Genes & Diseases, 2020, 7(3): 328-335.
|
| 16 |
Kim JH, Kim SY, Kim KP, et al. Regorafenib-induced hypothyroidism as a predictive marker for improved survival in metastatic or unresectable colorectal cancer refractory to standard therapies: a prospective single-center study[J]. Targeted Oncology, 2019, 14(6): 689-697.
|
| 17 |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nature Medicine, 2020, 26(4): 566-576.
|
| 18 |
News in Brief. PD-1 inhibitor bests chemo for colorectal cancer[J]. Cancer discovery, 2020, 10(7): Of2.
|
| 19 |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. The New England Journal of Medicine, 2020, 383(23): 2207-2218.
|
| 20 |
Fumet JD, Isambert N, Hervieu A, et al. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer[J]. ESMO Open, 2018, 3(4): e000375.
|
| 21 |
Park EJ, Baek JH, Choi GS, et al. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: a multicenter randomized controlled trial[J]. Cancers, 2020, 12(8): 2306.
|
| 22 |
Ergun Y, Bal O, Dogan M, et al. Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?[J] Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences, 2020, 25: 14.
|
| 23 |
Fiorentini G, Sarti D, Aliberti C, et al. Chemoembolization in conjunction with bevacizumab: Preliminary results[J]. Journal of Vascular and Interventional Radiology: JVIR, 2018, 29(9): 1236-1239.
|
| 24 |
Wei N, Zhang B, Wang Y, et al. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis[J]. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, 21(4): 443-450.
|
| 25 |
Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase Ⅱ trial[J]. Journal of the National Cancer Institute, 2017, 109(9): djx015.
|
| 26 |
Larsen FO, Jensen BV, Nørgaard HH, et al. Intrahepatic oxaliplatin and systemic 5-FU +/- cetuximab in chemo-naïve patients with liver metastases from colorectal cancer[J]. Oncology, 2019, 96(6): 299-308.
|
| 27 |
Coletti L, Battaglia V, De Simone P, et al. Safety and feasibility of electrochemotherapy in patients with unresectable colorectal liver metastases: A pilot study[J]. International Journal of Surgery (London, England), 2017, 44: 26-32.
|
| 28 |
Scorsetti M, Comito T, Clerici E, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up[J]. Radiation Oncology (London, England), 2018, 13(1): 234.
|
| 29 |
Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial[J]. The British Journal of Surgery, 2019, 106(13): 1837-1846.
|